ANDRES MANUEL R
CERVANTES RUIPEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
Memorial Sloan Kettering Cancer Center
Nueva York, Estados UnidosMemorial Sloan Kettering Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (17)
2024
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nature Medicine, Vol. 30, Núm. 1, pp. 271-278
2023
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935
-
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
ESMO Open, Vol. 8, Núm. 2
-
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
ESMO Open, Vol. 8, Núm. 3
2022
-
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3452-3463
2021
-
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer
Annals of Oncology, Vol. 32, Núm. 12, pp. 1496-1510
2020
-
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
Cancer discovery, Vol. 10, Núm. 2, pp. 198-213
-
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
British Journal of Cancer, Vol. 123, Núm. 11, pp. 1590-1598
2019
-
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
The Lancet Oncology, Vol. 20, Núm. 6, pp. 849-861
-
Definition of the rectum: An International, expert-based Delphi consensus
Annals of Surgery, Vol. 270, Núm. 6, pp. 955-959
-
Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors
Clinical Cancer Research, Vol. 25, Núm. 11, pp. 3220-3228
-
Summary of the International Conference on Onco-Nephrology: an emerging field in medicine
Kidney International, Vol. 96, Núm. 3, pp. 555-567
2018
-
Phase II study of Taselisib (GDC-0032) in combination with fulvestrant in patients with HER2-negative, hormone receptor–positive advanced breast cancer
Clinical Cancer Research, Vol. 24, Núm. 18, pp. 4380-4387
2015
-
Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: Preclinical characterization and phase I clinical trial
Clinical Cancer Research, Vol. 21, Núm. 1, pp. 49-59
2014
2013
-
Evaluation and clinical analyses of downstream targets of the akt inhibitor GDC-0068
Clinical Cancer Research, Vol. 19, Núm. 24, pp. 6976-6986
-
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement
Cancer Discovery, Vol. 3, Núm. 4, pp. 406-417